{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:24:52Z","timestamp":1792668292892,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,5,29]],"date-time":"2015-05-29T00:00:00Z","timestamp":1432857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,5,29]],"date-time":"2015-05-29T00:00:00Z","timestamp":1432857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bacterial resistance to almost all available antibiotics is an important public health issue. A major goal in antimicrobial drug discovery is the generation of new chemicals capable of killing pathogens with high selectivity, particularly multi-drug-resistant ones. Here we report the design, preparation and activity of new compounds based on a tunable, chemically accessible and upscalable lipopeptide scaffold amenable to suitable hit-to-lead development. Such compounds could become therapeutic candidates and future antibiotics available on the market. The compounds are cyclic, contain two D-amino acids for <jats:italic>in vivo<\/jats:italic> stability and their structures are reminiscent of other cyclic disulfide-containing peptides available on the market. The optimized compounds prove to be highly active against clinically relevant Gram-negative and Gram-positive bacteria. <jats:italic>In vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> tests show the low toxicity of the compounds. Their antimicrobial activity against resistant and multidrug-resistant bacteria is at the membrane level, although other targets may also be involved depending on the bacterial strain.<\/jats:p>","DOI":"10.1038\/srep10558","type":"journal-article","created":{"date-parts":[[2015,5,29]],"date-time":"2015-05-29T13:18:43Z","timestamp":1432905523000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["A bioinspired peptide scaffold with high antibiotic activity and low in vivo toxicity"],"prefix":"10.1038","volume":"5","author":[{"given":"Francesc","family":"Rabanal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Grau-Campistany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Vila-Farr\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Gonzalez-Linares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Borr\u00e0s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeles","family":"Manresa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Cajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,29]]},"reference":[{"key":"BFsrep10558_CR1","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1136\/bmj.c2115","volume":"340","author":"CM Morel","year":"2010","unstructured":"Morel, C. M. & Mossialos, E. Stoking the antibiotic pipeline. British Med. J. 340, 1115\u20131118 (2010).","journal-title":"British Med. J"},{"key":"BFsrep10558_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/472032a","volume":"472","author":"MA Cooper","year":"2011","unstructured":"Cooper, M. A. & Shlaes, D. Fix the antibiotic pipeline. Nature 472, 32 (2011).","journal-title":"Nature"},{"key":"BFsrep10558_CR3","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/ja.2013.86","volume":"66","author":"MS Butler","year":"2013","unstructured":"Butler, M. S., Blaskovich, M. A. & Cooper M. A. Antibiotics in the clinical pipeline in 2013. J. Antibiotics 66, 571\u2013591 (2013).","journal-title":"J. Antibiotics"},{"key":"BFsrep10558_CR4","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1093\/cid\/cit152","volume":"56","author":"HW Boucher","year":"2013","unstructured":"Boucher, H. W. et al. Infectious Diseases Society of America. 10\u00d7\u201920 Progress\u2014Development of new drugs active against gram-negative bacilli: an update from the infectious diseases society of America. Clin. Infect. Dis. 56, 1685\u20131694 (2013).","journal-title":"Clin. Infect. Dis."},{"key":"BFsrep10558_CR5","doi-asserted-by":"publisher","first-page":"S397","DOI":"10.1093\/cid\/cir153","volume":"52","author":"RJ Guidos","year":"2011","unstructured":"Guidos R. J., Infectious Diseases Society of America. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis. 52, S397\u2013S428 (2011).","journal-title":"Clin Infect Dis."},{"key":"BFsrep10558_CR6","unstructured":"Mossialos, E . et al. Policies and Incentives for Promoting Innovation in Antibiotic Research. (2009) Available at: http:\/\/www.lse.ac.uk\/LSEHealthAndSocialCare\/impacts\/LSEHealthNews\/News%20Attachments\/Policies%20and%20incentives%20report.pdf. (Date of access: 04\/02\/2015)"},{"key":"BFsrep10558_CR7","unstructured":"CDC, Centre for Disease Control and Prevention, Threat report 2013. (2014) Available at: http:\/\/www.cdc.gov\/drugresistance\/threat-report-2013 (Date of access: 04\/02\/2015)."},{"key":"BFsrep10558_CR8","doi-asserted-by":"publisher","first-page":"f1430","DOI":"10.1136\/bmj.f1430","volume":"346","author":"R Smith","year":"2013","unstructured":"Smith, R. & Coast, J. The true cost of antimicrobial resistance. British Med. J. 346, f1430 (2013).","journal-title":"British Med. J."},{"key":"BFsrep10558_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/ja.2013.49","volume":"67","author":"CT Walsh","year":"2014","unstructured":"Walsh, C. T. & Wencewicz, T. A. Prospects for new antibiotics: a molecule-centered perspective. J. Antibiotics 67, 7\u201322 (2014).","journal-title":"J. Antibiotics"},{"key":"BFsrep10558_CR10","unstructured":"World Health Organization. Antimicrobial Resistance: Global Report on Surveillance 2014. (2014) Available at: http:\/\/apps.who.int\/iris\/bitstream\/10665\/112642\/1\/9789241564748_eng.pdf (Date of access: 24\/02\/2015)."},{"key":"BFsrep10558_CR11","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/509555a","volume":"509","author":"M Woolhouse","year":"2014","unstructured":"Woolhouse, M. & Farrar J. An intergovernmental panel on antimicrobial resistance. Nature 509, 555\u2013557 (2014).","journal-title":"Nature"},{"key":"BFsrep10558_CR12","doi-asserted-by":"crossref","unstructured":"Editorial, A three-step plan for antibiotics, Nature 509, 533 (2014).","DOI":"10.1038\/509533a"},{"key":"BFsrep10558_CR13","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1086\/652237","volume":"50","author":"DN Gilbert","year":"2010","unstructured":"Gilbert D. N. et al. The 10x\u00b420 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin. Infect. Dis. 50, 1081\u20131083 (2010).","journal-title":"Clin. Infect. Dis."},{"key":"BFsrep10558_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/509141a","volume":"509","author":"S Reardon","year":"2014","unstructured":"Reardon, S. Antibiotic resistance sweeping developing world. Nature 509, 141\u2013142 (2014).","journal-title":"Nature"},{"key":"BFsrep10558_CR15","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nrmicro3245","volume":"12","author":"JH Rex","year":"2014","unstructured":"Rex J. H. ND4BB: addressing the antimicrobial resistance crisis. Nature Rev. Microbiol. 12, 231\u2013232 (2014).","journal-title":"Nature Rev. Microbiol."},{"key":"BFsrep10558_CR16","doi-asserted-by":"crossref","unstructured":"Vi\u00f1as, M., Rabanal, F., Benz, R., Vinuesa, T. & Fust\u00e9, E. in Antimicrobial compounds: current strategies and new alternatives (eds Villa, T. G. & Veiga-Crespo, P. ) Ch. 10, 269\u2013284 (Springer Verlag GmbH, 2014).","DOI":"10.1007\/978-3-642-40444-3_10"},{"key":"BFsrep10558_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrd3591","volume":"11","author":"CD Fjell","year":"2012","unstructured":"Fjell, C. D., Hiss, J. A., Hancock, R. E. W., & Schneider, G. Designing antimicrobial peptides: form follows function. Naure. Rev. Drug Discov. 11, 37\u201351 (2012).","journal-title":"Naure. Rev. Drug Discov"},{"key":"BFsrep10558_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3109\/07388551.2011.594423","volume":"32","author":"M Pasupuleti","year":"2012","unstructured":"Pasupuleti, M., Schmidtchen, A. & Malmsten, M. Antimicrobial peptides: key components of the innate immune system. Crit. Rev. Biotechnol. 32, 143\u2013171 (2012).","journal-title":"Crit. Rev. Biotechnol."},{"key":"BFsrep10558_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1124\/pr.55.1.2","volume":"55","author":"MR Yeaman","year":"2003","unstructured":"Yeaman, M. R. & Yount, N. Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 55, 27\u201355 (2003).","journal-title":"Pharmacol. Rev."},{"key":"BFsrep10558_CR20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1146\/annurev-pharmtox-010611-134535","volume":"52","author":"NY Yount","year":"2012","unstructured":"Yount, N. Y. & Yeaman, M. R. Emerging themes and therapeutic prospects for anti-infective peptides. Annu. Rev. Pharmacol. Toxicol. 52, 337\u2013360 (2012).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"BFsrep10558_CR21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nrmicro1098","volume":"3","author":"KA Brogden","year":"2005","unstructured":"Brogden, K. A. Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? Nature Rev. Microbiol. 3, 238\u2013250 (2005).","journal-title":"Nature Rev. Microbiol."},{"key":"BFsrep10558_CR22","first-page":"217","volume":"38","author":"NK Brogden","year":"2011","unstructured":"Brogden, N. K. & Brogden, K. A. Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals? Int. J. Antimicrob. Agents 38, 217\u2013225 (2011).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"BFsrep10558_CR23","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.1182749","volume":"327","author":"N Srinivas","year":"2010","unstructured":"Srinivas, N. et al. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science 327, 1010\u20131013 (2010).","journal-title":"Science"},{"key":"BFsrep10558_CR24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nrmicro908","volume":"2","author":"BB Finlay","year":"2004","unstructured":"Finlay, B. B. & Hancock, R. E. W. Can innate immunity be enhanced to treat microbial infections? Nat. Rev. Microbiol. 2, 497\u2013504 (2004).","journal-title":"Nat. Rev. Microbiol."},{"key":"BFsrep10558_CR25","doi-asserted-by":"publisher","first-page":"8856","DOI":"10.1073\/pnas.97.16.8856","volume":"97","author":"REW Hancock","year":"2000","unstructured":"Hancock, R. E. W. & Scott, M. G., The role of antimicrobial peptides in animal defences. Proc. Natl. Acad. Sci. USA 97, 8856\u20138861 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep10558_CR26","doi-asserted-by":"publisher","first-page":"7609","DOI":"10.1021\/ja8093247","volume":"131","author":"R Rathinakumar","year":"2009","unstructured":"Rathinakumar, R., Walkenhorst, W. F. & Wimley, W. C. Broad-spectrum antimicrobial peptides by rational combinatorial design and high-throughput screening: the importance of interfacial activity. J. Am. Chem. Soc. 131, 7609\u20137617 (2009).","journal-title":"J. Am. Chem. Soc."},{"key":"BFsrep10558_CR27","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1093\/jac\/dkt039","volume":"68","author":"M Vaara","year":"2013","unstructured":"Vaara, M. Novel derivatives of polymyxins. J. Antimicrob Chemother. 68, 1213\u20131219 (2013).","journal-title":"J. Antimicrob Chemother."},{"key":"BFsrep10558_CR28","unstructured":"Rabanal, F., Cajal, Y., Garcia-Subirats, M. & Rodr\u00edguez M., inventors; University of Barcelona assignee. Peptide compounds that can be used as antibacterial agents. United States patent US2013053305. 2010, March 10th"},{"key":"BFsrep10558_CR29","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nchem.1012","volume":"3","author":"F Nederberg","year":"2011","unstructured":"Nederberg, F. et al. Biodegradable nanostructures with selective lysis of microbial membranes. Nature Chemistry 3, 409\u2013414 (2011).","journal-title":"Nature Chemistry"},{"key":"BFsrep10558_CR30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nrmicro2474","volume":"9","author":"JG Hurdle","year":"2011","unstructured":"Hurdle, J. G., O\u2019Neill, A. J., Chopra, I. & Lee, R. E. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nature Rev. Microbiol. 9, 62\u201375 (2011).","journal-title":"Nature Rev. Microbiol."},{"key":"BFsrep10558_CR31","doi-asserted-by":"crossref","first-page":"10849","DOI":"10.1016\/S0021-9258(17)34136-4","volume":"269","author":"DP Clark","year":"1994","unstructured":"Clark, D. P., Durrel, S., Malloy, W. L. & Zasloff, M. Ranalexin, a novel antimicrobial peptide from Bullfrog (Rana Catesbeiana) skin, structurally related to the antibacterial antibiotic polymyxin. J. Biol. Chem. 269, 10849\u201310855 (1994).","journal-title":"J. Biol. Chem."},{"key":"BFsrep10558_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1126\/science.8420003","volume":"259","author":"A Rustici","year":"1993","unstructured":"Rustici, A. et al. Molecular mapping and detoxification of the lipid A binding site by synthetic peptides. Science 259, 361\u2013364 (1993).","journal-title":"Science"},{"key":"BFsrep10558_CR33","doi-asserted-by":"publisher","first-page":"5724","DOI":"10.1128\/AAC.01333-12","volume":"56","author":"K Abdelraouf","year":"2012","unstructured":"Abdelraouf, K., Jie, H., Ledesma, K. R., Hu, M. & Tam, V. H. Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob. Agents Chemother. 56, 5724\u20135727(2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep10558_CR34","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1128\/AAC.02557-14","volume":"58","author":"K Abdelraouf","year":"2014","unstructured":"Abdelraouf, K., Chang, K.-T., Yin, T., Hu, M. & Tam, V. H. Uptake of polymyxin B into renal cells. Antimicrob. Agents Chemother. 58, 4200\u20134202 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep10558_CR35","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1021\/mp200483t","volume":"9","author":"JJ Yang","year":"2012","unstructured":"Yang, J. J., Kularatne, S. A., Chen, X., Low, P. S. & Wang, E. Characterization of in vivo disulfide-reduction mediated drug release in mouse kidneys. Mol. Pharm. 9, 310\u2013317 (2012).","journal-title":"Mol. Pharm."},{"key":"BFsrep10558_CR36","doi-asserted-by":"publisher","first-page":"13872","DOI":"10.1073\/pnas.0601455103","volume":"103","author":"JJ Yang","year":"2006","unstructured":"Yang, J. J., Chen, H., Vlahov, I. R., Cheng, J.-X. & Low, P. S. Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging, Proc. Natl. Acad. Sci. USA 103, 13872\u201313877 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep10558_CR37","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1021\/bc300020f","volume":"23","author":"Q Geng","year":"2012","unstructured":"Geng, Q., Sun, X., Gong, T. & Zhang, Z.-R. Peptide\u2013drug conjugate linked via a disulfide bond for kidney targeted drug delivery. Bioconjugate Chem. 23, 1200\u20131210 (2012).","journal-title":"Bioconjugate Chem"},{"key":"BFsrep10558_CR38","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1021\/jm900999h","volume":"53","author":"T Velkov","year":"2010","unstructured":"Velkov, T., Thompson, P. E., Nation, R. L. & Li, J. Structure-activity relationships of polymyxin antibiotics. J. Med. Chem. 53, 1898\u20131916 (2010)","journal-title":"J. Med. Chem."},{"key":"BFsrep10558_CR39","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/00021369.1974.10861184","volume":"38","author":"S Chihara","year":"1974","unstructured":"Chihara, S., Yahata, M., Tobita, T. & Koyama, Y. Chemical synthesis, isolation and characterization of \u03b1-N-fattyacyl colistin nonapeptide with special reference to the correlation between antimicrobial activity and carbon number of fatty acyl moiety. Agric. Biol. Chem. 38, 521\u2013529 (1974).","journal-title":"Agric. Biol. Chem."},{"key":"BFsrep10558_CR40","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1021\/cb500080r","volume":"9","author":"T Velkov","year":"2014","unstructured":"Velkov, T. et al. Teaching \u2018Old\u2019 Polymyxins New Tricks: New-Generation Lipopeptides Targeting Gram-Negative \u2018Superbugs\u2019. ACS Chem. Biol. 9, 1172\u20131177 (2014).","journal-title":"ACS Chem. Biol."},{"key":"BFsrep10558_CR41","doi-asserted-by":"publisher","first-page":"5079","DOI":"10.1021\/jm400416u","volume":"56","author":"TV Magee","year":"2013","unstructured":"Magee T. V. et al. Discovery of Dap-3 polymyxin analogues for the treatment of multi-drug-resistant gram-negative nosocomial infections. J Med Chem. 56, 5079\u20135093 (2013).","journal-title":"J Med Chem."},{"key":"BFsrep10558_CR42","doi-asserted-by":"publisher","first-page":"4402","DOI":"10.1128\/AAC.00642-11","volume":"55","author":"M Sol\u00e9","year":"2011","unstructured":"Sol\u00e9, M. et al. First description of an Escherichia coli strain producing NDM-1 carbapenemase in Spain. Antimicrob. Agents Chemother. 55, 4402\u20134404 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep10558_CR43","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1128\/CMR.13.2.167","volume":"13","author":"A Alvarez-Barrientos","year":"2000","unstructured":"Alvarez-Barrientos, A., Arroyo, J., Canton, R., Nombela, C. & Sanchez-Perez, M. Applications of flow cytometry to clinical microbiology. Clinical Microbiology Reviews 13, 167\u2013195 (2000).","journal-title":"Clinical Microbiology Reviews"},{"key":"BFsrep10558_CR44","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/(SICI)1097-0320(19970901)29:1<58::AID-CYTO6>3.0.CO;2-9","volume":"29","author":"J Comas","year":"1997","unstructured":"Comas, J. & Vives-Rego, J. Assessment of the effects of gramicidin, formaldehyde and surfactants on Escherichia coli by flow cytometry using nucleic acid and membrane potential dyes. Cytometry 29, 58\u201364 (1997).","journal-title":"Cytometry"},{"key":"BFsrep10558_CR45","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1093\/jb\/mvp096","volume":"146","author":"T Mogi","year":"2009","unstructured":"Mogi, T. et al. Polymyxin B identified as an inhibitor of alternative NADH dehydrogenase and malate:quinone oxidoreductase from Gram-positive bacterium Mycobacterium smegmatis. J. Biochem. 146, 491\u2013499 (2009).","journal-title":"J. Biochem."},{"key":"BFsrep10558_CR46","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/ja.2013.111","volume":"67","author":"ZZ Deris","year":"2014","unstructured":"Deris, Z. Z. et al. A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADH-quinone oxidoreductase activity. J Antibiot. (Tokyo) 67, 147\u2013151 (2014).","journal-title":"J Antibiot. (Tokyo)"},{"key":"BFsrep10558_CR47","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1128\/AAC.44.8.2086-2092.2000","volume":"44","author":"CL Friedrich","year":"2000","unstructured":"Friedrich, C. L., Moyles, D., Beveridge, T. J. & Hancock R. E. W. Antibacterial action of structurally diverse cationic peptides on gram-positive bacteria. Antimicrob. Agents Chemother. 44, 2086\u20132092 (2000).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep10558_CR48","first-page":"105","volume":"24","author":"RL Santhana","year":"2007","unstructured":"Santhana R. L. et al. Mesosomes are a definite event in antibiotic-treated Staphylococcus aureus ATCC 25923. Tropical Biomedicine 24, 105\u2013109 (2007).","journal-title":"Tropical Biomedicine"},{"key":"BFsrep10558_CR49","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1021\/jp064757+","volume":"111","author":"A Clausell","year":"2007","unstructured":"Clausell, A. et al. Gram negative outer and inner membrane models: insertion of cyclic cationic lipopeptides. J. Phys. Chem. B 111, 551\u2013556 (2007).","journal-title":"J. Phys. Chem. B"},{"key":"BFsrep10558_CR50","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1021\/jp0551972","volume":"110","author":"A Clausell","year":"2006","unstructured":"Clausell, A., Rabanal, F., Garcia-Subirats, M., Alsina, M. A. & Cajal, Y. Membrane association and contact formation by a synthetic analogue of polymyxin B and its fluorescent derivatives. J Phys Chem B 110, 4465\u20134471 (2006).","journal-title":"J Phys Chem B"},{"key":"BFsrep10558_CR51","unstructured":"Jorgensen, J. H. & Turnidge, J. D. Antibacterial susceptibility test: dilutions and diffusion methods in Manual of Clinical Microbiology (eds Murray, P. R., Baron, E. J., Jorgensen, J. H., Pfaller, M. A. & Yorken, R. H. ) pp 1108 (ASM Press: Washington DC,, 2003)."},{"key":"BFsrep10558_CR52","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55\u201363 (1983).","journal-title":"J. Immunol. Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep10558","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep10558.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep10558.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T17:14:03Z","timestamp":1672938843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep10558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,29]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,9,22]]}},"alternative-id":["BFsrep10558"],"URL":"https:\/\/doi.org\/10.1038\/srep10558","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,29]]},"assertion":[{"value":"19 November 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10558"}}